

FOR IMMEDIATE RELEASE

Contact: Ronald Trahan, APR, Ronald Trahan Associates Inc., 508-359-4005, x108

**CoreValve announces successful completion of initial series of
proctored cases in Australia and New Zealand using its
ReValving[®] System for percutaneous aortic valve replacement**

**CoreValve to present clinical data at
“22nd EACTS Annual Meeting” in Lisbon, Portugal**

IRVINE, Calif., Sept. 8, 2008—CoreValve (www.corevalve.com) announced today that five (5) clinical evaluation sites—two in New Zealand and three in Australia—have now completed their first series of proctored cases using the Company’s proprietary *ReValving*[®] System for percutaneous aortic valve replacement (PAVR), which features a porcine pericardium valve mounted in a self-expanding frame.

During a 12-day period, 24 patients at hospitals in Auckland, Brisbane, Melbourne, Sydney and Hamilton underwent successful percutaneous aortic valve replacement with CoreValve’s *ReValving* System. These hospitals are participating in a clinical evaluation registry as required for market clearance in Australia and New Zealand. To date, more than 1,500 patients at 75 sites worldwide have now received a *ReValving* bioprosthesis since the CE Mark was issued. Physicians will be presenting CoreValve clinical data at the “22nd EACTS (European Association for Cardio-Thoracic Surgery) Annual Meeting in Lisbon, Portugal, which begins September 13th.

“We are gratified to see tremendous enthusiasm for our *ReValving* technology in Australia and New Zealand,” said Daniel Lemaitre, President and Chief Executive Officer of CoreValve. “More importantly, the clinical results generated by these pioneering centers are remarkable and a testimony to the ability to leverage the extensive European clinical experience that has catapulted us into the leadership position in the transfemoral aortic valve replacement market.”

About CoreValve

CoreValve, Inc., is headquartered in Irvine, Calif. Its proprietary *ReValving*[®] System allows both *percutaneous* aortic valve replacement (PAVR) and *transapical* aortic valve replacement (TAVR) and is intended to provide an alternative to open-heart surgery. The *ReValving* System procedures are performed on the beating heart without cardiac assistance or rapid pacing, and may result in less trauma to the patient. This technology may also offer substantial cost-savings to the healthcare system. The catheter-based technology includes a proprietary framed/self-expanding tissue heart valve that is specifically designed and engineered for transcatheter delivery. For more information about CoreValve, visit the Company’s Web site at www.corevalve.com.

(Caution: the CoreValve *ReValving* System will not be available in the USA for clinical trials or for sale until further notice.)

#